TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidance
The company raised its full-year 2026 revenue targets and reported positive Phase 3 data supporting a simplified BRIUMVI dosing regimen.
SEC filing
Latest
1 story
Sign inSign in1 story
The company raised its full-year 2026 revenue targets and reported positive Phase 3 data supporting a simplified BRIUMVI dosing regimen.
SEC filing